Inclusion Criteria:

- Signed written informed consent

- Male or female ≥18 years of age

- Cito-histological diagnosis of NSCLC, stage IV

- Performance Status = 0 or 1

- Measurable disease on CT scan - RECIST criteria

- White blood count ≥ 3 x 109/L, Neutrophils ≥ 1.5 x 109/L,

- platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL

- Bilirubin level either normal or ≤1.5 x ULN

- ASAT and ALAT ≤ 2.5 x ULN (or 5 x ULN in case of liver metastases)

- Alkaline phosphatase ≤ 2,5 x ULN or ≤ 5 x ULN in case of bone metastases

- Creatinine clearance ≥ 50 ml/min

- Negative pregnancy test within one week before treatment start, if applicable

- Life expectancy of ≥ 3 months

- Availability of tumor sample (or able and willing to provide tumor sample) for EGFR
assessment

- Effective contraception for both male and female patients if the risk of conception
exists

Exclusion Criteria:

- Documented or symptomatic brain metastases

- Previous chemotherapy for NSCLC including adjuvant chemotherapy

- Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
indicated in the study protocol

- Any investigational agent(s) within 4 weeks prior to entry

- Major surgery within 4 weeks prior to study entry

- Prior chest irradiation within 12 weeks prior to study entry (palliative radiation of
bone lesions is allowed)

- Superior vena cava syndrome contra-indicating hydratation

- Previous exposure to EGF, monoclonal antibodies, signal transduction inhibitors or
EGFR targeting therapy

- Myocardial infraction within 6 months prior to study entry, uncontrolled congestive
heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment

- Known allergic / hypersensitivity reaction to any of the components of study
treatments

- Known drug abuse/ alcohol abuse

- Legal incapacity or limited legal capacity

- Symptomatic peripheral neuropathy (NCI-CTC) ≥ 2 and/or ototoxicity grade ≥ 2 , except
if due to trauma or mechanical impairment due to tumor mass

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent

- Pregnancy or breastfeeding

- Any previous or concurrent malignancy other than nonmelanoma skin cancer, or
carcinoma in situ of the cervix. (Patients with a previous malignancy but without
evidence of disease for > 5 years will be allowed to enter the trial)